Department of Gynecology, Cancer Institute Hospital, Koto-ku, Tokyo 135-8550, Japan.
Int J Gynecol Cancer. 2012 May;22(4):573-8. doi: 10.1097/IGC.0b013e31823fd413.
Although postoperative adjuvant chemotherapy is generally recommended for early-stage ovarian cancer, it remains unclear whether adjuvant chemotherapy is also effective for clear cell carcinoma (CCC).
Seventy-three patients with stage I CCC of the ovary who had undergone complete surgical staging formed the study population (stage IA, 20 patients; stage IC, 53 patients). Survival and multivariate analyses were retrospectively performed to determine the effectiveness of postoperative chemotherapy in these patients.
Of the total (73 patients), 30 patients received adjuvant chemotherapy (stage I C-positive), whereas 43 patients did not (stage I C-negative). The 5-year progression-free survival (PFS) and 5-year overall survival (OS) rates for the stage I C-positive group were 80.1% and 87.4% compared with 73.9% and 81.7% for the stage I C-negative group. The differences in survival between these groups were not significant (PFS: P = 0.610; OS: P = 0.557). Four of the patients with stage IA CCC underwent chemotherapy, whereas the remaining 16 patients received no additional therapy. No recurrence was observed in either group. Of the patients with stage IC CCC, 26 patients underwent chemotherapy (stage IC C-positive) and 27 received no additional therapy (stage IC C-negative). There was no statistical difference in PFS and OS between the stage IC C-positive and stage IC C-negative groups. Of the patients with stage IC without artificial rupture, the 5-year PFS rates of the C-positive and C-negative patients were 69.6% and 34.6%, respectively, but the 5-year OS rates were 75.0% and 70.0%, respectively (not significant). Multivariate analyses confirmed that the presence or absence of adjuvant chemotherapy was not a prognostic indicator.
The current study was performed only in fully staged patients, suggesting that postoperative adjuvant chemotherapy is not necessary for stage IA CCC patients. For patients with stage IC CCC patients, adjuvant chemotherapy suppressed recurrence, but the effectiveness was insufficient in our limited study. Further studies are required to clarify this.
尽管术后辅助化疗通常被推荐用于早期卵巢癌,但对于透明细胞癌(CCC)是否也有效仍不清楚。
73 例接受完全手术分期的 I 期 CCC 卵巢癌患者形成研究人群(IA 期 20 例;IC 期 53 例)。回顾性进行生存和多因素分析,以确定这些患者术后化疗的有效性。
在总数(73 例)中,30 例患者接受了辅助化疗(I 期 C 阳性),而 43 例患者未接受(I 期 C 阴性)。I 期 C 阳性组的 5 年无进展生存期(PFS)和 5 年总生存期(OS)率分别为 80.1%和 87.4%,而 I 期 C 阴性组分别为 73.9%和 81.7%。两组之间的生存差异无统计学意义(PFS:P=0.610;OS:P=0.557)。4 例 IA 期 CCC 患者接受化疗,而其余 16 例患者未接受任何额外治疗。两组均无复发。在 IC 期 CCC 患者中,26 例患者接受化疗(IC 期 C 阳性),27 例患者未接受额外治疗(IC 期 C 阴性)。IC 期 C 阳性和 IC 期 C 阴性组之间的 PFS 和 OS 无统计学差异。在未行人工破裂的 IC 期患者中,C 阳性和 C 阴性患者的 5 年 PFS 率分别为 69.6%和 34.6%,但 5 年 OS 率分别为 75.0%和 70.0%(无显著性差异)。多因素分析证实,辅助化疗的有无不是预后指标。
本研究仅在完全分期的患者中进行,提示 IA 期 CCC 患者术后无需辅助化疗。对于 IC 期 CCC 患者,辅助化疗抑制了复发,但在我们的有限研究中效果不足。需要进一步的研究来阐明这一点。